2025年Q1,没有一家制药巨头笑的出来,即便是增速可怕的礼来。 如果说,2024年Q1,制药巨头的重心还在向内“开刀”,降本增效,到了2025年Q1,其最头疼的问题,除了化解产品“青黄不接”的尴尬局面外,还有如何抵御地缘政治、监管变化、潜在关税及多重外部压力带来的长远困扰。 据外媒统计,一季度,营收位列顶尖阵营的25家制药巨头里,有7家收入同比下降,值得一提的是,7家公司全部来自美国。其中下滑最...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.